Department of Justice November 22, 2017 – Federal Register Recent Federal Regulation Documents

First Choice Surgery Center of Baton Rouge, L.L.C.; Decision and Order
Document Number: 2017-25288
Type: Notice
Date: 2017-11-22
Agency: Drug Enforcement Administration, Department of Justice
Arnold E. Feldman, M.D.; Decision and Order
Document Number: 2017-25287
Type: Notice
Date: 2017-11-22
Agency: Drug Enforcement Administration, Department of Justice
Linda M. Shuck, D.O.; Decision and Order
Document Number: 2017-25286
Type: Notice
Date: 2017-11-22
Agency: Drug Enforcement Administration, Department of Justice
Bulk Manufacturer of Controlled Substances Registration
Document Number: 2017-25285
Type: Notice
Date: 2017-11-22
Agency: Drug Enforcement Administration, Department of Justice
Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration as bulk manufacturers of various classes of schedule I and II controlled substances.
Importer of Controlled Substances Registration
Document Number: 2017-25284
Type: Notice
Date: 2017-11-22
Agency: Drug Enforcement Administration, Department of Justice
Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration as importers of various classes of schedule I or II controlled substances.
Schedules of Controlled Substances: Placement of FDA-Approved Products of Oral Solutions Containing Dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in Schedule II
Document Number: 2017-25275
Type: Rule
Date: 2017-11-22
Agency: Drug Enforcement Administration, Department of Justice
This final rule adopts without changes an interim final rule with request for comments published in the Federal Register on March 23, 2017. On July 1, 2016, the U.S. Food and Drug Administration (FDA) approved a new drug application for Syndros, a drug product consisting of dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] oral solution. The Drug Enforcement Administration (DEA) maintains FDA- approved products of oral solutions containing dronabinol in schedule II of the Controlled Substances Act.